Gene therapy for aids using retroviral mediated gene transfer to deliver hiv-1 antisense tar and transdominant rev protein genes to syngeneic lymphocytes in hiv-1 infected identical twins

Human Gene Therapy

Volumn 7, Issue 10, 1996, Pages 1281-1306

  Morgan, Richard A ^a   Walker, Robert ^a  

^a CGTB ^*

Author keywords

[No Author keywords available]

Indexed keywords

REV PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOPTIVE TRANSFER; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL PROTOCOL; CLINICAL TRIAL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LONG TERMINAL REPEAT; METHODOLOGY; MOLONEY LEUKEMIA ONCOVIRUS; MONOZYGOTIC TWINS; NUCLEIC ACID PROBE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REGULATOR GENE; TWINS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOPTIVE TRANSFER; ANTISENSE ELEMENTS (GENETICS); CD4-POSITIVE T-LYMPHOCYTES; CLINICAL PROTOCOLS; DISEASES IN TWINS; GENE PRODUCTS, REV; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, REV; GENETIC VECTORS; HIV LONG TERMINAL REPEAT; HIV SEROPOSITIVITY; HIV-1; HUMANS; MOLONEY MURINE LEUKEMIA VIRUS; TWINS, MONOZYGOTIC;

EID: 0030594579     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.10-1281     Document Type: Article

References (49)

1. Estimates of HJV-1 prevalence and projected AIDS cases: summary of a workshop October 31-November 1, 1989. MMWR 39:110-119(1990).
2. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retrovirus (HTLV-ni) from patients with AIDS and at risk for AIDS. Science 224:500 (1984).
3. Barre-Sinoussi F, Nugeyre M, Dauguet C, et al. Isolation of a Tlymphotropic retrovirus from a patients at risk for acquired immune deficiency syndrome. Science 220:868 (1983).
4. Popovic M, Sarngadbaron MO, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retrovirus (HTLV-Hf) from patients with AIDS and pre-AIDS. Science 224:497 (1984).
5. Curran JW, Jaffe HW, Hardy AM. Epidemiology of HTV-1 infection and AIDS in the United States. Science 239:610 (1988).
6. Mann J, Chin J, Piot P, Quinn T. The International Epidemiology of AIDS. Scientific American 259:82-89 (1988).
7. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine in the treatment of patients with AIDS and ATDS-related complex. N Engl J Med 317:185-191 (1987).
8. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 322:941-949 (1990).
9. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HTV) infection. Ann Intern Med 112:727-737 (1990).
10. Friedland GH. Early treatment for HTV: the time has come. N Engl i Med 322:1000-1002 (1990).
11. Ruedy J, Schlechter M, Montaner JSG. Zidovudine for early human immunodeficiency virus (HTV) infection: Who, when, and how? Ann Intern Med 112:721-723 (1990).
12. Fauci AS. Combination therapy for HTV-1 infection: getting closer. Ann Intern Med 116:85-86 (1992).
13. Fischl MA, Richman DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA 262:2405-2410 (1989).
14. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 321:1621-1625 (1989).
15. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 317:192-197 (1987).
16. Larder BA, Darby G, Richman DD. HTV-1 with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734(1989).
17. Kenny AB, Hitzig WH. Bone marrow transplantation for severe combined immunodeficiency disease. Reported from 1968 to 1977. EUT J Pediatr 131:155-177 (1979).
18. Vossen JM. Bone marrow transplantation in the treatment of primary immunodeficiencies. Ann Clin Res 19:285-292 (1987).
19. Boron MM, Rimm AA. Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. JAMA 238:591-600 (1977).
20. Lane HC, Kovacs JA, Feinberg J. Anti-retroviral effects of interferonalpha in AIDS-associated Kaposi's sarcoma. Lancet 2:1218-1222 (1988).
21. Rook AH, Masur H, Lane HC, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immunodeficiency syndrome. J Clin Invest 72:398-403 (1987).
22. Lane HC, Masur H, Longo D, et al. Partial immune reconstitution in a patient with the acquired immunodeficiency syndrome. N Engl J Med 311:1099-1103 (1984).
23. Mitsuyasu R, Volberding P, Groopman J, et al. Bone marrow transplantation from identical twins in the treatment of AIDS and Kaposi's sarcoma [Abstract]. J Cell Biochem 8A:22 (1987).
24. Hassen JM, Zaroulis CG, Greenberg ML, et al. Bone marrow transplantation in AIDS [Letter]. N Engl J Med 309:665 (1983).
25. Davis KC, Hayward A, Ozturk G, et al. Lymphocyte transfusion in case of acquired immunodeficiency syndrome [Letter]. Lancet 1:599-600 (1983).
26. Vilmer E, Rhodes-Feuillette A, Rabian C, et al. Clinical and immunological restoration in patients with AIDS after marrow transplantation, using lymphocyte transfusions from the marrow donor. Transplantation 44:25-29 (1987).
27. Verdonck LF, de Gast GC, Lange JM, et al. Syngeneic leukocytes together with suramin failed to improve immunodeficiency in a case of transfusion-associated AIDS after syngeneic bone marrow transplantation. Blood 71:666-671 (1988).
28. Lane HC, Zunich KM, Wilson W, et al. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HTV) infection. Ann Intern Med 113:512-519 (1990).
29. Morgan, R.A., and Anderson, W.F. 1993. Human gene therapy. Ann. Rev. Biochem. 62:191-217.
30. VandenDriessche, T., Chuah, M.K.L., and Morgan, R.A. 1994. Gene therapy for acquired immune deficiency syndrome, p. 1-14. In: V.T. DeVita, S. Hellman, and S.A. Rosenberg (eds.), AIDS updates, vol. 7 (4), J.B. Lippincott Co., Philadelphia, PA.
31. Malim, M.H., Bohnlein, S., Hauber, J., and Cullen, B.R. 1989. Functional dissection of the HTV-1 Rev trans-activator: derivation of a trans-dominant represser of Rev function. Cell 58:205-214.
32. Chuah, M.K.L., VandenDriessche, T., Chang, H., Ensoli, B., and Morgan, R.A. Inhibition of human immunodeficiency virus type1 by retroviral vectors expressing antisense TAR. Hum Gene Therapy, In press.
33. Nabel, G.J., Fox, B.A., Post, L., Thompson, C.B., and Woffendin, C. 1994. A molecular genetic intervention for AIDS-Effects of a transdominant negative form of Rev. Hum. Gene Ther. 5:79-92.
34. Fisher, U., Meyer, S., Teufel, M., Heckel, C., Luhrmann, R., and Rautmann, G. 1994. Evidence that HTV-1 Rev directly promotes the nuclear export of unspliced RNA. The EMBO J. 13 (17):4105-4112.
35. Hope, T.J., Klein, N.P., Elder, M.E., & Parslow, T.G. 1992. Transdominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes. J. Virol. 66:1849-1855.
36. Jack A. Regheb, Peter Bressler, Marybeth Daucher, Lydia Chiang, Marinee K.L. Chuah, Thierry VandenDriessche, and Richard A. Morgan. Analysis of Transdominant Mutants of the HIV-1 Rev Protein for Their Ability to Inhibit Rev Function, HTV-1 Replication, and their use as anti-HIV-1 Gene Therapeutics. Submitted.
37. Theirry VandenDriessche 1, Marinee K.L. Chuahl,2, Lydia Chiangl, Hsiao-Kuey Chang3, Barbara Ensoh'3 and Richard A. Morganl Inhibition Of Clinical HTV-1 Isolates In Primary CD4+ T Lymphocytes By Retroviral Vectors Expressing Anti-HTV-1 Genes, Submitted.
38. Ensoli, B., Barillari, G., Salahuddin, S.Z., Gaüo, R.C., and WongStaal, F. 1990. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 344:84-86.
39. Laurence, J., and Astrin, S.M. 1991. Human immunodeficiency virus induction of malignant transformation in human B lymphocytes. Proc. Natl. Acad. Sei. U.S.A. 88:7635-7639.
40. Sabatier, J.-M., E. Vives, K. Mabrouk, A. Benjouad, H. Rochat, A. Duval, B. Hue, and E. Bahraoui. 1991. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J. Virol. 65:961-967.
41. Crowe, S.M., Mills, J., Elbeik, T., et al: 1992. Human immuno-deficiency virus-infected monocyte-derived macrophages express surface GP120 and fuse with CD4 lymphoid cells in vitro: A possible mechanism of T lymphocyte depletion in vivo. Clin Immunol Immunopathol 65:143-151.
42. Banda, N.K., Bernier, J., Kurahara, D.K., et al: 1992. Crosslinking CD4 by human immunodeficiency virus gp!20 primes T cells for activation-induced apoptosis. J. Exp. Med. 176: 1099-1106.
43. HiU, J.M., Mervis, R.F., Avidor, R., et al: 1993. fflV-1 envelope protein-induced neuronal damage and retardation of behavioral development hi rat neonates. Brain Res 603:222-233.
44. Rosenberg SA, Aebersold P, Cornelia K, el al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infillraling lymphocytes modified by retroviral gene iransduction. New Engl J Med 323:570-578 (1990).
45. Abrahamsen TG, Carter CS, Rubin M, et al. Large scale séparation of peripheral blood monocytes: Influence of elutriation medium and storage conditions on inflammatory mediator release. J Clin Apheresis 6:48-53, 1991.
46. Carter CS, Leilman SF, Cullis H, el al. Technical aspecls of lymphokine-activated killer production. J Clin Apheresis 4:113-117, 1988.
47. Aebersold P, Carter CS, Hyatl C, el al. A simplified automated procedure for generation of lymphokine-activated killer cells for use in clinical trials. J Immunol Methods 112:1-7, 1988.
48. Muul LM, Nason-Burchenal K, Carter CS, el al. Developmenl of an automated closed system for generation of human lymphokineactivated killer (LAK) cells for use in adoptive immunotherapy. J Immunol Methods 101:171-181, 1987.
49. Carter CS, Leilman SF, Cullis H, el al. Use of a continuous-flow cell separator in density gradient isolation of lymphocytes. Transfusion 27:362-365, 1987.